What is HC Wainwright’s Forecast for CTXR Q3 Earnings?

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) – Equities researchers at HC Wainwright issued their Q3 2026 earnings estimates for Citius Pharmaceuticals in a report released on Monday, May 18th. HC Wainwright analyst S. Ramakanth expects that the company will post earnings per share of ($0.36) for the quarter. HC Wainwright has a “Buy” rating and a $4.00 price objective on the stock. HC Wainwright also issued estimates for Citius Pharmaceuticals’ Q4 2026 earnings at ($0.25) EPS, Q1 2027 earnings at ($0.28) EPS, Q2 2027 earnings at ($0.20) EPS, Q3 2027 earnings at ($0.19) EPS, Q4 2027 earnings at ($0.16) EPS and FY2027 earnings at ($0.81) EPS.

Several other brokerages also recently issued reports on CTXR. D. Boral Capital reaffirmed a “buy” rating and issued a $6.00 price objective on shares of Citius Pharmaceuticals in a research report on Wednesday, March 11th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Citius Pharmaceuticals in a research report on Friday, March 27th. Two research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $5.00.

Citius Pharmaceuticals Stock Down 24.8%

Shares of NASDAQ:CTXR opened at $0.53 on Tuesday. Citius Pharmaceuticals has a 52-week low of $0.48 and a 52-week high of $2.48. The company has a 50 day moving average of $0.78 and a two-hundred day moving average of $0.91. The company has a market capitalization of $11.79 million, a price-to-earnings ratio of -0.22 and a beta of 1.05.

Citius Pharmaceuticals (NASDAQ:CTXR) last issued its quarterly earnings data on Friday, May 15th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.39 by ($1.34). The business had revenue of $1.67 million for the quarter, compared to the consensus estimate of $18.79 million.

Hedge Funds Weigh In On Citius Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in CTXR. XTX Topco Ltd purchased a new position in shares of Citius Pharmaceuticals during the 2nd quarter valued at approximately $32,000. NewEdge Advisors LLC purchased a new position in shares of Citius Pharmaceuticals during the 2nd quarter valued at approximately $40,000. Asset Advisory Group Inc. purchased a new position in shares of Citius Pharmaceuticals during the 4th quarter valued at approximately $46,000. Finally, Heights Capital Management Inc. purchased a new position in shares of Citius Pharmaceuticals during the 4th quarter valued at approximately $622,000. 16.88% of the stock is currently owned by hedge funds and other institutional investors.

Citius Pharmaceuticals Company Profile

Citius Pharmaceuticals is a clinical‐stage specialty pharmaceutical company focused on the development and commercialization of critical care products and novel drug delivery systems. Headquartered in Cranford, New Jersey, the company aims to address unmet medical needs in acute care, hospital‐acquired infections and subcutaneous delivery of biologics. Citius operates as a Delaware corporation and trades on the NASDAQ under the symbol CTXR.

One of the company’s leading assets is Mino-Lok, an antibiotic lock solution designed to treat catheter‐related bloodstream infections without catheter removal.